Extension usage examples:
Here's how our browser extension sees the article:
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy - PubMed
Source: pubmed.ncbi.nlm.nih.gov
Article summary:
1. CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has demonstrated efficacy in treating B-cell malignancies, but is associated with toxicities including cytokine release syndrome (CRS), neurotoxicity, and impaired hematopoietic recovery.
2. A retrospective analysis of 173 patients who received defined-composition CD19 CAR T-cell therapy identified increased CRS severity as an independent predictor for decreased platelet count and lower prelymphodepletion platelet count as an independent predictor of both decreased neutrophil and platelet counts after CD19 CAR T-cell infusion.
3. Higher peak serum concentrations of interleukin-6 were associated with lower day-28 cell counts, while higher serum concentrations of transforming growth factor-β1 were associated with higher counts.
Article analysis:
The article is generally reliable and trustworthy, as it provides a detailed analysis of 173 patients who received defined-composition CD19 CAR T-cell therapy in a phase 1/2 clinical trial. The authors used debiased least absolute shrinkage selector and operator regression analysis for high-dimensional modeling to identify factors independently associated with hematologic toxicity following CD19 CAR T-cell therapy. Furthermore, they identified associations between higher peak serum concentrations of interleukin-6 and lower day 28 cell counts, as well as between higher serum concentrations of transforming growth factor β1 and higher counts.
However, there are some potential biases that should be noted when considering the trustworthiness and reliability of this article. First, the study was conducted retrospectively which may lead to selection bias or other methodological issues that could affect the results. Additionally, the study only included 173 patients which may not be sufficient to draw definitive conclusions about the effects of CD19 CAR T-cell therapy on hematologic toxicity. Finally, there is no discussion about potential risks or side effects associated with this type of treatment which should be considered when evaluating its safety and efficacy.